Literature DB >> 26621528

Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999-2014).

Gian Gandhi1.   

Abstract

BACKGROUND: GAVI's focus on reducing inequities in access to vaccines, immunization, and GAVI funds, - both between and within countries - has changed over time. This paper charts that evolution.
METHODS: A systematic qualitative review was conducted by searching PubMed, Google Scholar and direct review of available GAVI Board papers, policies, and program guidelines. Documents were included if they described or evaluated GAVI policies, strategies, or programs and discussed equity of access to vaccines, utilization of immunization services, or GAVI funds in countries currently or previously eligible for GAVI support. Findings were grouped thematically, categorized into time periods covering GAVI's phases of operations, and assessed depending on whether the approaches mediated equity of opportunity or equity of outcomes between or within countries.
RESULTS: Serches yielded 2816 documents for assessment. After pre-screening and removal of duplicates, 552 documents underwent detailed evaluation and pertinent information was extracted from 188 unique documents. As a global funding mechanism, GAVI responded rationally to a semi-fixed funding constraint by focusing on between-country equity in allocation of resources. GAVI's predominant focus and documented successes have been in addressing between-country inequities in access to vaccines comparing lower income (GAVI-eligible) countries with higher income (ineligible) countries. GAVI has had mixed results at addressing between-country inequities in utilization of immunization services, and has only more recently put greater emphasis and resources towards addressing within-country inequities in utilization to immunization services. Over time, GAVI has progressively added vaccines to its portfolio. This expansion should have addressed inter-country, inter-regional, inter-generational and gender inequities in disease burden, however, evidence is scant with respect to final outcomes.
CONCLUSION: In its next phase of operations, the Alliance can continue to demonstrate its strength as a highly effective multi-partner enterprise, capable of learning and innovating in a world that has changed much since its inception. By building on its successes, developing more coherent and consistent approaches to address inequities between and within countries and by monitoring progress and outcomes, GAVI is well-positioned to bring the benefits of vaccination to previously unreached and underserved communities towards provision of universal health coverage.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26621528      PMCID: PMC4665898          DOI: 10.1186/s12889-015-2521-8

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  68 in total

Review 1.  The introduction of new vaccines into developing countries.

Authors:  R T Mahoney; J E Maynard
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

2.  Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.

Authors:  Richard Rheingans; Deborah Atherly; John Anderson
Journal:  Vaccine       Date:  2012-04-27       Impact factor: 3.641

3.  GAVI and the Vaccine Fund--a boon for immunization in the developing world.

Authors:  K A Balaji
Journal:  Indian J Public Health       Date:  2004 Apr-Jun

4.  Reaching Every District (RED) approach: a way to improve immunization performance.

Authors:  Jos Vandelaer; Julian Bilous; Deo Nshimirimana
Journal:  Bull World Health Organ       Date:  2008-03       Impact factor: 9.408

5.  The response to flexibility: country intervention choices in the first four rounds of the GAVI Health Systems Strengthening applications.

Authors:  Lieve Goeman; Benedicte Galichet; Denis G Porignon; Peter S Hill; Naima Hammami; Marthe-Sylvie Essengue Elouma; Patrick Y Kadama; Wim Van Lerberghe
Journal:  Health Policy Plan       Date:  2010-02-01       Impact factor: 3.344

Review 6.  Defining equity in health.

Authors:  P Braveman; S Gruskin
Journal:  J Epidemiol Community Health       Date:  2003-04       Impact factor: 3.710

7.  The impact of new vaccine introduction on the coverage of existing vaccines: a cross-national, multivariable analysis.

Authors:  Jessica C Shearer; Damian G Walker; Nicholas Risko; Orin S Levine
Journal:  Vaccine       Date:  2012-10-23       Impact factor: 3.641

8.  Gates, GAVI, the glorious global funds and more: all you ever wanted to know.

Authors:  Gustav J V Nossal
Journal:  Immunol Cell Biol       Date:  2003-02       Impact factor: 5.126

9.  Reassessing the value of vaccines.

Authors:  Till Bärnighausen; Seth Berkley; Zulfiqar A Bhutta; David M Bishai; Maureen M Black; David E Bloom; Dagna Constenla; Julia Driessen; John Edmunds; David Evans; Ulla Griffiths; Peter Hansen; Farah Naz Hashmani; Raymond Hutubessy; Dean T Jamison; Prabhat Jha; Mark Jit; Hope Johnson; Ramanan Laxminarayan; Bruce Y Lee; Sharmila Mhatre; Anne Mills; Anders Nordström; Sachiko Ozawa; Lisa Prosser; Karlee Silver; Christine Stabell Benn; Baudouin Standaert; Damian Walker
Journal:  Lancet Glob Health       Date:  2014-04-23       Impact factor: 26.763

10.  Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.

Authors:  Ann Levin; Susan A Wang; Carol Levin; Vivien Tsu; Raymond Hutubessy
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

View more
  9 in total

1.  An equity dashboard to monitor vaccination coverage.

Authors:  Catherine Arsenault; Sam Harper; Arijit Nandi; José M Mendoza Rodríguez; Peter M Hansen; Mira Johri
Journal:  Bull World Health Organ       Date:  2016-11-21       Impact factor: 9.408

2.  Predictors of Health-Care Utilization Among Children 6-59 Months of Age in Zambézia Province, Mozambique.

Authors:  Mary Bayham; Meridith Blevins; Melanie Lopez; Omo Olupona; Lazaro González-Calvo; Elisée Ndatimana; Ann F Green; Troy D Moon
Journal:  Am J Trop Med Hyg       Date:  2016-11-07       Impact factor: 2.345

3.  Determinants of full vaccination status in children aged 12-23 months in Gurùé and Milange districts, Mozambique: results of a population-based cross-sectional survey.

Authors:  Shellese A Shemwell; Meridith B Peratikos; Lázaro González-Calvo; Montse Renom-Llonch; Alexandre Boon; Samuel Martinho; Charlotte B Cherry; Ann F Green; Troy D Moon
Journal:  Int Health       Date:  2017-07-01       Impact factor: 2.473

Review 4.  Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.

Authors:  Marie-Anne Boujaoude; Andrew J Mirelman; Kim Dalziel; Natalie Carvalho
Journal:  Cost Eff Resour Alloc       Date:  2018-05-18

5.  Tracking coverage, dropout and multidimensional equity gaps in immunisation systems in West Africa, 2000-2017.

Authors:  Oghenebrume Wariri; Bassey Edem; Esin Nkereuwem; Oluwatosin O Nkereuwem; Gregory Umeh; Ed Clark; Olubukola T Idoko; Terna Nomhwange; Beate Kampmann
Journal:  BMJ Glob Health       Date:  2019-09-06

6.  Financing intersectoral action for health: a systematic review of co-financing models.

Authors:  Finn McGuire; Lavanya Vijayasingham; Anna Vassall; Roy Small; Douglas Webb; Teresa Guthrie; Michelle Remme
Journal:  Global Health       Date:  2019-12-18       Impact factor: 4.185

Review 7.  Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All.

Authors:  Theano Lagousi; Ioanna Papadatou; Petros Strempas; Elena Chatzikalil; Vana Spoulou
Journal:  Vaccines (Basel)       Date:  2021-11-24

8.  Applying GRADE-CERQual to qualitative evidence synthesis findings-paper 7: understanding the potential impacts of dissemination bias.

Authors:  Andrew Booth; Simon Lewin; Claire Glenton; Heather Munthe-Kaas; Ingrid Toews; Jane Noyes; Arash Rashidian; Rigmor C Berg; Brenda Nyakang'o; Joerg J Meerpohl
Journal:  Implement Sci       Date:  2018-01-25       Impact factor: 7.327

9.  Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.

Authors:  David FitzSimons; Greet Hendrickx; Johannes Hallauer; Heidi Larson; Daniel Lavanchy; Ina Lodewyckx; Daniel Shouval; John Ward; Pierre Van Damme
Journal:  Hepatol Med Policy       Date:  2016-12-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.